London-based pan-emerging markets private equity firm Actis has made a bid for Adcock Ingram, South Africa's second-biggest pharmaceutical company, Business Day reported, quoting an unnamed source close to the deal. Actis has declined to comment. Earlier this month, Adcock said that it was evaluating non-binding proposals from unnamed bidders that could lead to the acquisition of 100% of the company or a controlling stake in it.
Adcock’s board turned down last month a ZAR 6.2bn (EUR 501.4mn) offer for a 60% stake from South African industrial conglomerate Bidvest Group, saying Bidvest’s proposal was not made correctly. It has not received a new proposal from Bidvest, but Bidvest has said it hoped that Adcock shareholders would be given the opportunity to vote on its previous offer, turning to a potential hostile bid.
JSE-listed Adcock Ingram has been underperforming since 2008, when it was unbundled from South Africa's biggest foods maker Tiger Brands, and analysts have described it as a long-overdue takeover target.
Botswana's government has granted a uranium prospecting licence to ASX-listed Pioneer Lithium Limited (Pioneer). The firm said in a release on July 15 that the Botsalano Uranium Project ... more
South Africa’s Electricity and Energy Minister Kgosientsho Ramokgopa has presented a revised plan to achieve energy access for all South Africans by 2030. In his Budget Vote speech at the National ... more
Egypt and Russia have signed a supplementary intergovernmental agreement to push forward the El-Dabaa nuclear power plant project in Egypt, Al Arabiya reported on July 8, citing a statement from ... more